{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:31:49Z","timestamp":1793971909189,"version":"4.8.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2009,10,1]],"date-time":"2009-10-01T00:00:00Z","timestamp":1254355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":2253,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1097\/jto.0b013e3181b6be57","type":"journal-article","created":{"date-parts":[[2009,9,19]],"date-time":"2009-09-19T04:52:55Z","timestamp":1253335975000},"page":"1270-1273","source":"Crossref","is-referenced-by-count":92,"title":["Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas"],"prefix":"10.1016","volume":"4","author":[{"given":"Giuseppe","family":"Giaccone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Rajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ruijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cees","family":"van Groeningen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pancras C.W.","family":"Hogendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3181b6be57_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00277-002-0597-6","article-title":"Malignant thymoma: current status of classification and multimodality treatment","volume":"82","author":"Schmidt-Wolf","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib2","series-title":"Histological Typing of Tumors of the Thymus","author":"Rosai","year":"1999"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ijrobp.2003.11.021","article-title":"Thymic carcinoma: state of the art review","volume":"59","author":"Eng","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib4","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00432-004-0545-z","article-title":"Tyrosine kinase receptor expression in thymomas","volume":"130","author":"Henley","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib5","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/path.1514","article-title":"KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas","volume":"202","author":"Pan","year":"2004","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa011573","article-title":"Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia","volume":"346","author":"Kantarjian","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib7","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","article-title":"Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor","volume":"21","author":"Heinrich","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(04)17098-0","article-title":"Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial","volume":"364","author":"Verweij","year":"2004","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib9","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ejca.2008.06.003","volume":"44","author":"Sciot","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO;2-2","article-title":"Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients","volume":"192","author":"de Leeuw","year":"2000","journal-title":"J Pathol"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib11","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2005.02.093","article-title":"KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors","volume":"23","author":"Sihto","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib12","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib13","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.lungcan.2008.03.035","article-title":"Absence of gene mutations in KIT-positive thymic epithelial tumors","volume":"62","author":"Tsuchida","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib14","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.lungcan.2008.03.013","article-title":"Mutational status of EGFR and KIT in thymoma and thymic carcinoma","volume":"62","author":"Yoh","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib15","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.bjc.6604482","article-title":"Phase II trial of imatinib mesylate in patients with metastatic melanoma","volume":"99","author":"Kim","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1097\/JTO.0b013e3181b6be57_bib16","doi-asserted-by":"crossref","first-page":"452s","DOI":"10.1200\/jco.2008.26.15_suppl.8116","article-title":"Imatinib in the treatment of thymic carcinoma","volume":"26","author":"Salter","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415312302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415312302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T14:39:48Z","timestamp":1558535988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415312302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,10]]},"references-count":16,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["S1556086415312302"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3181b6be57","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2009,10]]}}}